Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Recruiting · NCT06543069 · Registry updated 2024-08-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | malignant peritoneal mesothelioma | Recruiting | Phase 2 | 2024-08-07 | NCT06543069 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Institute and Hospital,Chinese Academy of Medical Sciences | Beijing | China | 1 |